Evidence map›Paper›PMID 36942434›Full record

ArticleJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2026

Multiple cardiotoxicities during osimertinib therapy.

Hasan Kobat, Michael Davidson, Islam Elkonaissi, Emma Foreman, Shereen Nabhani-Gebara

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Hasan KobatDepartment of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University London, Kingston Upon Thames, UK.ORCID 0000-0003-1194-6427
Michael DavidsonLung Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Islam ElkonaissiSheikh Shakhbout Medical City, Abu Dhabi, UAE.
Emma ForemanPharmacy Department, The Royal Marsden NHS Foundation Trust, London, UK.ORCID 0000-0002-4348-9040
Shereen Nabhani-GebaraDepartment of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University London, Kingston Upon Thames, UK.
Kingston University · GBRoyal Marsden NHS Foundation Trust · GBSheikh Shakhbout Medical City · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionThe tyrosine-kinase inhibitor osimertinib is an oral anti-cancer agent that is used for the treatment of patients with metastatic non-small cell lung cancer harbouring sensitising

Indexed as

AcrylamidesAniline CompoundsAntineoplastic AgentsCardiotoxicityLong QT SyndromePiperazinesAgedAtrial FibrillationCarcinoma, Non-Small-Cell LungElectrocardiographyHeart FailureHumansIndolesLung NeoplasmsMaleProtein Kinase InhibitorsAcrylamidesAniline CompoundsAntineoplastic AgentsIndolesosimertinibPiperazinesProtein Kinase InhibitorsPyrimidinesanti-cancer treatmentcardiotoxicitycase reportdrug safetyLung cancer

Identifiers

PMID36942434
PMCPMC13018250
OpenAlexW4328049048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.